NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EXO Biologics

EXO Biologics

Private
LiègeHealthcare & Life Scienceshttps://www.exobio.be/en/

Last Round

Series A

Apr 24, 2024

Total Funding Raised

$27.56M

Company Overview

EXO Biologics is a biopharma company that is developing biopharmaceuticals using Extracellular Vesicles (EVs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

exosomesCDMOexosome therapyexosome manufacturingextracellular vesiclesGMP manufacturingclinical-stage biotechcontract development and manufacturing organizationrare disease therapyBronchopulmonary DysplasiaBPDorphan drug developmentEVsdrug deliverybioprocessingMSC-derived exosomes

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EXO Biologics Comparables

Compare EXO Biologics with similar companies based on industry and business-model similarity.

EXO Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EVerZom
86%
ILIAS Biologics Inc.
78%
Evox Therapeutics
76%

EXO Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 24, 2024
GrantFeb 5, 2021
Convertible DebtFeb 5, 2021

Key People

Founding team and executive leadership

Anne- Lien Thys

CFO

Executive Team

EXO Biologics Investors

Notable investors and investment history

EXO Biologics investors
InvestorRounds
NoshaqSeries A, Convertible Debt
Founders FundSeries A
Walloon Region (Belgium)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2025

    Monthly visitors increased 141% MoM.

  • Apr 24, 2024

    $17M round with participation from Founders Fund and Noshaq.

EXO Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EXO Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EXO Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLiège
Employee Range17
Year Founded2019
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.